



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/630,355	07/30/2003	Carsten Momma	117163.00077	9258
21324 7590 12/19/2007 HAHN LOESER & PARKS, LLP One GOJO Plaza Suite 300 AKRON, OH 44311-1076			EXAMINER PELLEGRINO, BRIAN E	
			ART UNIT 3738	PAPER NUMBER
			NOTIFICATION DATE 12/19/2007	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@hahnlaw.com
akron-docket@hotmail.com

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10630355	7/30/03	MOMMA ET AL.	117163.00077

HAHN LOESER & PARKS, LLP
One GOJO Plaza
Suite 300
AKRON, OH 44311-1076

EXAMINER

Brian E. Pellegrino

ART UNIT	PAPER
3738	20071113

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Applicant's reply brief alleges there is no reason to modify the Wu implantable device. However, a prima facie obviousness requires a teaching that all elements of the claimed invention are found in the prior art and a reason that would have prompted a person of ordinary skill in the relevant field to modify the prior art to arrive at the claimed invention. See KSR, 127 S. Ct. at 1741, 82 USPQ2d at 1396. In this instance all the structural elements of the claim are found in the Wu patent. The Examiner discusses the reason to modify the dimensions of the microcannula to be longer to penetrate a thicker covering and into tissue as disclosed by Wu. The reply brief filed 11/26/07 has been considered and entered. The application has been forwarded to the Board of Patent Appeals and Interferences for decision on the appeal.

BRIAN E. PELLEGRINO
PRIMARY EXAMINER